Jump Financial’s Janux Therapeutics JANX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.95M Sell
344,611
-17,054
-5% -$287K 0.04% 542
2026
Q2
$5.56M Buy
361,665
+139,865
+63% +$2.03M 0.04% 478
2026
Q1
$3.08M Buy
221,800
+125,116
+129% +$1.72M 0.04% 490
2025
Q4
$1.33M Sell
96,684
-83,016
-46% -$1.95M 0.02% 858
2025
Q3
$4.39M Sell
179,700
-48,730
-21% -$1.19M 0.05% 446
2025
Q2
$5.28M Buy
228,430
+134,400
+143% +$3.54M 0.06% 398
2025
Q1
$2.54M Buy
+94,030
New +$3.54M 0.03% 511
2024
Q3
– Sell
-18,100
Closed -$758K – 1882
2024
Q2
$758K Buy
18,100
+2,409
+15% +$113K 0.02% 946
2024
Q1
$591K Buy
+15,691
New +$342K 0.02% 1082
2023
Q3
– Sell
-10,821
Closed -$128K – 2050
2023
Q2
$128K Buy
+10,821
New +$145K ﹤0.01% 1614

Other funds holding JANX

Jump Financial's JANX Position: Q3 2026 in Review

Jump Financial reduced its Janux Therapeutics (JANX) stake by 4.7% in Q3 2026, selling an estimated $287K and leaving 344,611 shares worth $5.95M. The position accounts for 0.04% of the portfolio, ranked #542.

Jump Financial first reported a position in JANX in Q2 2023 and has held it in 10 quarters since. 204 funds tracked by Wall St. Rank hold JANX as of Q3 2026.

  • Jump Financial held 344,611 shares of Janux Therapeutics worth $5.95M as of Q3 2026.
  • Jump Financial sold 17,054 Janux Therapeutics shares in Q3 2026, an estimated $287K.
  • Janux Therapeutics made up 0.04% of Jump Financial's portfolio in Q3 2026, its #542 holding.
  • Jump Financial first reported a position in Janux Therapeutics in Q2 2023 and has held it in 10 quarters since.
  • 204 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2026.

Based on Jump Financial's 13F filing for Q3 2026, filed 13 Nov 2026.